A title for the grant UGA-T-MoFPED has not been specified.
Tuberculosis (TB) remains a major public health problem in Uganda causing unnecessary morbidity and mortality in the country. Uganda is ranked among the 22 TB high burden countries with prevalence and incidence of all forms of TB estimated at 193 and 209 per 100,000 populations respectively. This Program calls for a scale-up of TB prevention, control, treatment, care and support in Uganda in order to attain the global case notification and treatment targets and eventually the Millennium Development Goals (MDG). The Program proposes to achieve this through several objectives including assuring a regular uninterrupted supply of quality anti-TB drugs to TB patients (including MDR-TB patients); increasing access to quality bacteriology for TB diagnosis; strengthening TB/HIV collaboration; and strengthening TB control in Uganda Prisons. The goal of the Program is to reduce the morbidity and mortality attributable to TB in Uganda and the targeted groups are TB patients; HIV co-infected TB patients; Prison inmates and workers; and the general population. The Program is a consolidation of Round 10 and Round 6 TB grants.
- ID Projet
47045-UGA-T-MoFPED- Statut de l'activité
- 2 - Implementation
- Type d'aide
- C01 - Interventions de type projet
- % to Ouganda
- 100.00
Organisations
- Funding
- The Global Fund to Fight AIDS, Tuberculosis and Malaria
- Implementing
- Ministry of Finance, Planning and Economic Development of the Republic of Uganda
Versements par exercice fiscal, trimestre
| Exercice fiscal |
Trimestre fiscal |
Montant (USD) |
Ouganda Montant (USD) |
| 2018 |
Q1 |
1,693,945.00 |
1,693,945.00 |
| 2017 |
Q4 |
2,016,145.00 |
2,016,145.00 |
| 2017 |
Q3 |
5,474,673.00 |
5,474,673.00 |
| 2017 |
Q2 |
3,259,653.00 |
3,259,653.00 |
| 2017 |
Q1 |
4,818,875.00 |
4,818,875.00 |
| 2016 |
Q4 |
2,236.00 |
2,236.00 |
| 2016 |
Q3 |
1,040,180.00 |
1,040,180.00 |
| 2016 |
Q2 |
1,549,146.00 |
1,549,146.00 |
| 2016 |
Q1 |
788,304.00 |
788,304.00 |
| 2015 |
Q4 |
4,116,408.00 |
4,116,408.00 |
| 2015 |
Q3 |
3,959,954.00 |
3,959,954.00 |
| 2015 |
Q2 |
1,443,140.00 |
1,443,140.00 |
| 2015 |
Q1 |
1,168,683.00 |
1,168,683.00 |
| 2014 |
Q4 |
9,476,863.00 |
9,476,863.00 |
| 2014 |
Q2 |
957,278.00 |
957,278.00 |
| 2013 |
Q4 |
1,306,811.00 |
1,306,811.00 |
| 2013 |
Q2 |
5,357,121.00 |
5,357,121.00 |
| 2013 |
Q1 |
1,283,191.00 |
1,283,191.00 |
| 2012 |
Q4 |
399,178.00 |
399,178.00 |
| 2012 |
Q2 |
536,677.00 |
536,677.00 |
| 2011 |
Q4 |
3,643,106.00 |
3,643,106.00 |
| 2011 |
Q3 |
6,239,481.00 |
6,239,481.00 |
Engagements par exercice fiscal, trimestre
| Exercice fiscal |
Trimestre fiscal |
Montant (USD) |
Ouganda Montant (USD) |
| 2017 |
Q4 |
1,216,507.00 |
1,216,507.00 |
| 2017 |
Q3 |
10,240,499.00 |
10,240,499.00 |
| 2017 |
Q2 |
285,099.00 |
285,099.00 |
| 2017 |
Q1 |
1,157,604.00 |
1,157,604.00 |
| 2016 |
Q4 |
-44,459.00 |
-44,459.00 |
| 2016 |
Q3 |
11,543,228.00 |
11,543,228.00 |
| 2016 |
Q2 |
1,489,108.00 |
1,489,108.00 |
| 2016 |
Q1 |
636,470.00 |
636,470.00 |
| 2015 |
Q4 |
744,257.00 |
744,257.00 |
| 2015 |
Q1 |
5,597,508.00 |
5,597,508.00 |
| 2014 |
Q4 |
-3,152,082.00 |
-3,152,082.00 |
| 2014 |
Q2 |
8,752,121.00 |
8,752,121.00 |
| 2013 |
Q4 |
-6,318,075.00 |
-6,318,075.00 |
| 2013 |
Q3 |
16,173,630.00 |
16,173,630.00 |
Projections de CDMT par exercice fiscal
| Exercice fiscal |
Montant (USD) |
Ouganda Montant (USD) |
| 2017 |
5,081,627.00 |
5,081,627.00 |
| 2016 |
8,802,941.00 |
8,802,941.00 |
| 2015 |
7,818,655.00 |
7,818,655.00 |
| 2014 |
5,990,147.00 |
5,990,147.00 |
| 2013 |
2,514,975.00 |
2,514,975.00 |
| 2012 |
7,957,524.00 |
7,957,524.00 |
| 2011 |
7,044,213.00 |
7,044,213.00 |
| Code CRS |
% |
|
Lutte contre la tuberculose
(12263)
|
100.0
|